Related references
Note: Only part of the references are listed.Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
Samantha N. Champion et al.
MODERN PATHOLOGY (2020)
Comparative analysis of CEACAM1 expression in thin melanomas with and without regression
Luciana Nichita et al.
ONCOLOGY LETTERS (2019)
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Helen Adderley et al.
EBIOMEDICINE (2019)
PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
Samaresh Sau et al.
CANCERS (2019)
Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma
Iris Helfrich et al.
CANCERS (2019)
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
Yanhui Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Rational design of anti-GITR-based combination immunotherapy
Roberta Zappasodi et al.
NATURE MEDICINE (2019)
Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes
Anna Rachel Young et al.
CANCERS (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma
Wei-Ge Wang et al.
LABORATORY INVESTIGATION (2019)
Adaptation and memory in immune responses
Gioacchino Natoli et al.
NATURE IMMUNOLOGY (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Adverse Events Following Cancer Immunotheraoy: Obstacles and Opportunities
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2019)
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer
Chongkai Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Grazia R. Tundo et al.
CHEMOTHERAPY (2019)
Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review
Vignesh Ravi et al.
DERMATOLOGIC THERAPY (2019)
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
Mark P. Labrecque et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma
Henning Zelba et al.
CANCER IMMUNOLOGY RESEARCH (2019)
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Antje Tunger et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives
Malgorzata Bobrowicz et al.
CANCERS (2019)
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
Alberto Vogrig et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati et al.
BRITISH JOURNAL OF CANCER (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Jorge Blando et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Efficacy of CEACAM1-targeting immunoglobulin in combination with pembrolizumab in lung cancer
Jae-Hwan Kim et al.
CANCER RESEARCH (2019)
New emerging targets in cancer immunotherapy: the role of TIM3
Alex Friedlaender et al.
ESMO OPEN (2019)
New emerging targets in cancer immunotherapy: the role of LAG3
Hannah Christina Puhr et al.
ESMO OPEN (2019)
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
Catherine A. Sabatos-Peyton et al.
ONCOIMMUNOLOGY (2018)
Application of Genome Editing Techniques in Immunology
Agata O. Zych et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2018)
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
Florent Amatore et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model
Avner Friedman et al.
PLOS ONE (2018)
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
John K. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Eradication of spontaneous malignancy by local immunotherapy
Idit Sagiv-Barfi et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Next generation immune-checkpoints for cancer therapy
Chiara Donini et al.
JOURNAL OF THORACIC DISEASE (2018)
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Alice L. Hung et al.
ONCOIMMUNOLOGY (2018)
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
John E. Mullinax et al.
FRONTIERS IN ONCOLOGY (2018)
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L. Solomon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Estefania Paula Julia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors
Ben Tran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors
Romualdo Barroso-Sousa et al.
CURRENT ONCOLOGY REPORTS (2018)
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
S. Michael Chin et al.
NATURE COMMUNICATIONS (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
Guoying Zhou et al.
GASTROENTEROLOGY (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
Immunoregulatory functions of VISTA
Elizabeth C. Nowak et al.
IMMUNOLOGICAL REVIEWS (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
Jian-Feng Liu et al.
MOLECULAR ONCOLOGY (2017)
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Christian Kellner et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2017)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice
Lucas A. Horn et al.
ONCOTARGET (2017)
Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen- Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas
Jinhu Li et al.
MEDICAL SCIENCE MONITOR (2017)
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
Inna Serganova et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
The Feasibility and safety of surgery in Patients receiving immune checkpoint inhibitors: a retrospective study
Alexandra W. Elias et al.
FRONTIERS IN ONCOLOGY (2017)
Monoclonal Antibodies for the Treatment of Cancer
Joseph Thomas Pento
ANTICANCER RESEARCH (2017)
Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy
Elisabeth Perez-Ruiz et al.
CLINICAL CANCER RESEARCH (2017)
Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.
Paolo Antonio Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet
Gabriele D'Errico et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Reversing T-cell Dysfunction and Exhaustion in Cancer
Hassane M. Zarour
CLINICAL CANCER RESEARCH (2016)
Rationale for anti-OX40 cancer immunotherapy
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer
Seiichi Ikeda et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
Paola Savoia et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity
Gal Markel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Profiling cancer testis antigens in non-small-cell lung cancer
Dijana Djureinovic et al.
JCI INSIGHT (2016)
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. Louise Lines et al.
CANCER RESEARCH (2014)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
Sabrina Ceeraz et al.
ARTHRITIS RESEARCH & THERAPY (2014)
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Wenfeng Fang et al.
ONCOTARGET (2014)
Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review
Daniel M. Geynisman et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Kaori Sakuishi et al.
ONCOIMMUNOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
ICOS Mediates the Generation and Function of CD4+CD25+ Foxp3+ Regulatory T Cells Conveying Respiratory Tolerance
Mandy Busse et al.
JOURNAL OF IMMUNOLOGY (2012)
Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Rona Ortenberg et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Inflammatory cytokines as a third signal for T cell activation
Julie M. Curtsinger et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Safety of biologics, lessons learnt from TGN1412
Richard Stebbings et al.
CURRENT OPINION IN BIOTECHNOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The Role of OX40-Mediated Co-stimulation in T-Cell Activation and Survival
William L. Redmond et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2009)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Anti-CD70 antibodies:: a potential treatment for EBV+ CD70-expressing lymphomas
BF Israel et al.
MOLECULAR CANCER THERAPEUTICS (2005)
A critical role for the programmed death ligand 1 in fetomaternal tolerance
I Guleria et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis
MM Mazanet et al.
JOURNAL OF IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
ICOS co-stimulatory receptor is essential for T-cell activation and function
C Dong et al.
NATURE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Facilitation of β selection and modification of positive selection in the thymus of PD-1-deficient mice
H Nishimura et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
